Q-omics provides the consensus-scored EBLN3P profile across patient tissues and cancer cell-line models. EBLN3P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EBLN3P is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, EBLN3P RNA expression shows 20,890 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where EBLN3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EBLN3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EBLN3P survival associations across molecular data types. EBLN3P RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EBLN3P RNA expression–survival associations across cancer types. High EBLN3P expression shows unfavorable associations in ACC and UVM, but favorable associations in KIRC, SKCM, UCS and OV. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EBLN3P RNA expression.
This table summarizes EBLN3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for EBLN3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EBLN3P shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, COAD, STAD and BRCA. The HNSC box plot shows higher EBLN3P RNA expression in tumor versus normal tissue (log2 FC = +0.771, t-test p < 0.001).
This table shows molecular features associated with EBLN3P in patient tissues and cancer cell lines. In patient samples, EBLN3P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
